Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Total Current Liabilities (2016 - 2025)

CytomX Therapeutics' Total Current Liabilities history spans 12 years, with the latest figure at $46.6 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 45.65% year-over-year to $46.6 million; the TTM value through Dec 2025 reached $46.6 million, down 45.65%, while the annual FY2025 figure was $46.6 million, 45.65% down from the prior year.
  • Total Current Liabilities reached $46.6 million in Q4 2025 per CTMX's latest filing, up from $41.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $155.9 million in Q4 2023 to a low of $39.2 million in Q2 2025.
  • Average Total Current Liabilities over 5 years is $99.7 million, with a median of $91.0 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 95.98% in 2022, then tumbled 72.54% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $77.9 million in 2021, then surged by 95.98% to $152.6 million in 2022, then rose by 2.17% to $155.9 million in 2023, then tumbled by 44.99% to $85.8 million in 2024, then crashed by 45.65% to $46.6 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Total Current Liabilities are $46.6 million (Q4 2025), $41.0 million (Q3 2025), and $39.2 million (Q2 2025).